Can-Fite BioPharma Ltd. (TASE:CFBI) today reported "another significant finding" in its Phase I/II clinical trial of CF102 for the treatment of liver cancer. The new finding follows the announcement earlier this month that the safety and efficacy trial had achieved its primary and secondary endpoints.
Analysis by the company of the connection between the target receptor (A3), which CF102 attacks, and the patients' reaction to the drug found that in 85% of the cases, there was an overreaction by the receptor and corresponding improvement in the patients taking the drug. This finding indicates that the A3 receptor can serve as a biomarker to predict the patients' reaction to treatment with CF102.
Can-Fite CEO Pnina Fishman said, "First, the finding is further proof of the validity and importance of the receptor targeted by CF102. Second, this opens the possibility of using this biomarker to examine in advance whether patients are suitable for treatment with the drug, which will enable more effective and focused treatment on patients who can be expected to respond to the treatment."
Can-Fite's share price rose 2.7% in morning trading to NIS 0.49, giving a market cap of NIS 120 million.
Published by Globes [online], Israel business news - www.globes-online.com - on January 18, 2012
© Copyright of Globes Publisher Itonut (1983) Ltd. 2012